 Virginia Borges
Concepts (544)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 125 | 2023 | 1872 | 12.750 |
Why?
| | Pregnancy Complications, Neoplastic | 14 | 2021 | 50 | 3.260 |
Why?
| | Postpartum Period | 18 | 2022 | 281 | 3.020 |
Why?
| | Receptor, ErbB-2 | 28 | 2023 | 302 | 2.450 |
Why?
| | Receptors, Estrogen | 19 | 2021 | 372 | 2.160 |
Why?
| | Cancer Survivors | 14 | 2023 | 203 | 1.960 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2023 | 76 | 1.920 |
Why?
| | Mastectomy | 16 | 2022 | 99 | 1.870 |
Why?
| | Antineoplastic Agents, Hormonal | 11 | 2022 | 139 | 1.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 1360 | 1.570 |
Why?
| | Lactation | 9 | 2021 | 149 | 1.430 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 7 | 2023 | 50 | 1.250 |
Why?
| | Female | 141 | 2023 | 60070 | 1.240 |
Why?
| | Breast | 10 | 2021 | 139 | 1.160 |
Why?
| | Neoplasm Metastasis | 10 | 2020 | 526 | 1.080 |
Why?
| | Antineoplastic Agents | 12 | 2023 | 1891 | 1.080 |
Why?
| | Trastuzumab | 13 | 2023 | 89 | 1.030 |
Why?
| | Protein Kinase Inhibitors | 6 | 2021 | 789 | 1.010 |
Why?
| | Receptors, Progesterone | 6 | 2021 | 319 | 0.960 |
Why?
| | Mammary Glands, Human | 7 | 2020 | 60 | 0.950 |
Why?
| | Adult | 79 | 2023 | 30814 | 0.940 |
Why?
| | Pregnancy | 29 | 2023 | 5555 | 0.920 |
Why?
| | Triple Negative Breast Neoplasms | 6 | 2020 | 157 | 0.910 |
Why?
| | Humans | 150 | 2023 | 115859 | 0.890 |
Why?
| | Supreme Court Decisions | 1 | 2022 | 10 | 0.850 |
Why?
| | Brain Neoplasms | 9 | 2023 | 979 | 0.800 |
Why?
| | Mammary Glands, Animal | 9 | 2021 | 116 | 0.800 |
Why?
| | Carcinoma | 3 | 2021 | 200 | 0.780 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2022 | 638 | 0.740 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 27 | 0.740 |
Why?
| | BRCA2 Protein | 4 | 2022 | 42 | 0.720 |
Why?
| | Neoadjuvant Therapy | 6 | 2021 | 301 | 0.720 |
Why?
| | Maternal Age | 1 | 2020 | 117 | 0.690 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 82 | 0.680 |
Why?
| | Estradiol | 5 | 2019 | 453 | 0.660 |
Why?
| | Prognosis | 15 | 2022 | 3344 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 13 | 2023 | 862 | 0.640 |
Why?
| | Middle Aged | 50 | 2023 | 27078 | 0.620 |
Why?
| | Carcinoma in Situ | 3 | 2022 | 44 | 0.610 |
Why?
| | Parity | 7 | 2022 | 99 | 0.600 |
Why?
| | Lymphatic Metastasis | 10 | 2021 | 276 | 0.590 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1177 | 0.590 |
Why?
| | Young Adult | 32 | 2022 | 10508 | 0.560 |
Why?
| | Liver Neoplasms | 4 | 2016 | 521 | 0.550 |
Why?
| | Prospective Studies | 26 | 2023 | 6276 | 0.520 |
Why?
| | Cyclooxygenase 2 | 5 | 2020 | 165 | 0.520 |
Why?
| | Semaphorins | 3 | 2020 | 21 | 0.510 |
Why?
| | Antigens, CD | 5 | 2020 | 443 | 0.490 |
Why?
| | Melanoma | 4 | 2018 | 649 | 0.480 |
Why?
| | Aromatase Inhibitors | 6 | 2019 | 49 | 0.480 |
Why?
| | Mutation | 10 | 2023 | 3371 | 0.480 |
Why?
| | Capecitabine | 5 | 2023 | 46 | 0.480 |
Why?
| | Carcinoma, Lobular | 2 | 2012 | 44 | 0.470 |
Why?
| | Mastectomy, Segmental | 6 | 2022 | 76 | 0.470 |
Why?
| | Skin Neoplasms | 4 | 2013 | 760 | 0.470 |
Why?
| | Oxazoles | 4 | 2021 | 29 | 0.470 |
Why?
| | Combined Modality Therapy | 10 | 2023 | 1127 | 0.450 |
Why?
| | Quality of Life | 9 | 2022 | 2390 | 0.450 |
Why?
| | Puerperal Disorders | 2 | 2014 | 31 | 0.440 |
Why?
| | Chemotherapy, Adjuvant | 12 | 2023 | 334 | 0.440 |
Why?
| | Anxiety | 7 | 2022 | 854 | 0.420 |
Why?
| | Stromal Cells | 3 | 2013 | 97 | 0.420 |
Why?
| | Biomarkers, Tumor | 10 | 2023 | 1045 | 0.410 |
Why?
| | Quinazolines | 4 | 2021 | 241 | 0.410 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2021 | 448 | 0.410 |
Why?
| | Epithelial Cells | 6 | 2018 | 961 | 0.390 |
Why?
| | Fertility Preservation | 4 | 2021 | 47 | 0.390 |
Why?
| | BRCA1 Protein | 3 | 2022 | 57 | 0.380 |
Why?
| | Sexual Partners | 3 | 2022 | 164 | 0.380 |
Why?
| | Nevus, Pigmented | 1 | 2011 | 34 | 0.370 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 445 | 0.370 |
Why?
| | Disease-Free Survival | 7 | 2023 | 621 | 0.370 |
Why?
| | Pyridines | 4 | 2021 | 425 | 0.360 |
Why?
| | Radiosurgery | 3 | 2021 | 298 | 0.360 |
Why?
| | Tamoxifen | 7 | 2021 | 192 | 0.350 |
Why?
| | Estrogens | 4 | 2015 | 316 | 0.350 |
Why?
| | Cyclophosphamide | 5 | 2020 | 218 | 0.340 |
Why?
| | Gene Expression Profiling | 8 | 2020 | 1550 | 0.340 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1758 | 0.340 |
Why?
| | Adjuvants, Immunologic | 2 | 2022 | 206 | 0.340 |
Why?
| | Neoplasms | 6 | 2022 | 2114 | 0.340 |
Why?
| | Thrombophilia | 1 | 2009 | 67 | 0.330 |
Why?
| | Breast Feeding | 4 | 2020 | 370 | 0.320 |
Why?
| | Doxorubicin | 5 | 2020 | 290 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1143 | 0.320 |
Why?
| | Mice | 20 | 2021 | 15085 | 0.320 |
Why?
| | Animals | 30 | 2021 | 32158 | 0.320 |
Why?
| | Employment | 2 | 2019 | 139 | 0.310 |
Why?
| | Decision Making | 4 | 2022 | 790 | 0.300 |
Why?
| | Fertility | 4 | 2022 | 130 | 0.300 |
Why?
| | Breast Neoplasms, Male | 2 | 2018 | 28 | 0.300 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 816 | 0.300 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 2749 | 0.290 |
Why?
| | Adaptation, Psychological | 2 | 2022 | 551 | 0.290 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2018 | 54 | 0.280 |
Why?
| | Maytansine | 2 | 2018 | 13 | 0.280 |
Why?
| | Risk Factors | 14 | 2022 | 8715 | 0.280 |
Why?
| | Time Factors | 7 | 2020 | 6182 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 688 | 0.280 |
Why?
| | Cohort Studies | 10 | 2022 | 4960 | 0.270 |
Why?
| | Disease Management | 3 | 2021 | 563 | 0.270 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 524 | 0.270 |
Why?
| | Macrophages | 4 | 2018 | 1282 | 0.260 |
Why?
| | GPI-Linked Proteins | 3 | 2020 | 54 | 0.260 |
Why?
| | Reproductive History | 2 | 2015 | 12 | 0.260 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1088 | 0.250 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 76 | 0.250 |
Why?
| | Dimethyl Sulfoxide | 1 | 2005 | 43 | 0.250 |
Why?
| | Disease Progression | 10 | 2020 | 2423 | 0.250 |
Why?
| | Adolescent | 19 | 2022 | 17935 | 0.240 |
Why?
| | Aged | 24 | 2023 | 19292 | 0.240 |
Why?
| | Bupropion | 1 | 2004 | 39 | 0.240 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3587 | 0.240 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 165 | 0.240 |
Why?
| | Lymph Nodes | 3 | 2019 | 423 | 0.230 |
Why?
| | Liver | 3 | 2020 | 1693 | 0.230 |
Why?
| | Premenopause | 4 | 2021 | 104 | 0.230 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 380 | 0.220 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 724 | 0.220 |
Why?
| | Diarrhea | 3 | 2019 | 173 | 0.220 |
Why?
| | Cell Proliferation | 5 | 2021 | 2196 | 0.220 |
Why?
| | Estrogen Receptor alpha | 2 | 2021 | 120 | 0.220 |
Why?
| | Age Factors | 9 | 2021 | 2911 | 0.220 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2023 | 45 | 0.220 |
Why?
| | Proteomics | 2 | 2020 | 855 | 0.210 |
Why?
| | Incidence | 4 | 2020 | 2336 | 0.210 |
Why?
| | Pharmaceutical Preparations | 1 | 2005 | 169 | 0.210 |
Why?
| | Genomic Instability | 1 | 2022 | 38 | 0.210 |
Why?
| | Chromatography, Liquid | 1 | 2004 | 346 | 0.210 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 153 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2022 | 2201 | 0.210 |
Why?
| | Aurora Kinase A | 2 | 2019 | 51 | 0.210 |
Why?
| | Pilonidal Sinus | 1 | 2001 | 2 | 0.200 |
Why?
| | Condylomata Acuminata | 1 | 2001 | 6 | 0.200 |
Why?
| | Hematopoiesis | 1 | 2022 | 175 | 0.200 |
Why?
| | Tumor Microenvironment | 6 | 2021 | 424 | 0.200 |
Why?
| | Nausea | 2 | 2018 | 103 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2021 | 666 | 0.190 |
Why?
| | Mass Spectrometry | 1 | 2004 | 643 | 0.190 |
Why?
| | Ki-67 Antigen | 2 | 2019 | 104 | 0.190 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.180 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 964 | 0.180 |
Why?
| | Body Image | 3 | 2020 | 75 | 0.180 |
Why?
| | Resistance Training | 1 | 2022 | 124 | 0.180 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 30 | 0.180 |
Why?
| | Mice, Inbred BALB C | 6 | 2019 | 1169 | 0.180 |
Why?
| | Neoplasm Grading | 5 | 2021 | 244 | 0.180 |
Why?
| | Ibuprofen | 2 | 2018 | 73 | 0.180 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.180 |
Why?
| | Benzodiazepines | 1 | 2021 | 115 | 0.180 |
Why?
| | Biopsy | 4 | 2018 | 1056 | 0.180 |
Why?
| | Risk | 3 | 2013 | 829 | 0.170 |
Why?
| | Bone Neoplasms | 2 | 2016 | 194 | 0.170 |
Why?
| | Fatigue | 2 | 2018 | 296 | 0.170 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 562 | 0.170 |
Why?
| | Sexual Health | 1 | 2020 | 47 | 0.170 |
Why?
| | Pyrazoles | 3 | 2018 | 362 | 0.170 |
Why?
| | p21-Activated Kinases | 1 | 2019 | 14 | 0.170 |
Why?
| | Social Support | 3 | 2022 | 538 | 0.170 |
Why?
| | Cell Adhesion | 1 | 2020 | 433 | 0.170 |
Why?
| | Cell Communication | 1 | 2020 | 280 | 0.160 |
Why?
| | Receptor, trkB | 1 | 2019 | 28 | 0.160 |
Why?
| | Immunohistochemistry | 8 | 2019 | 1644 | 0.160 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2019 | 31 | 0.160 |
Why?
| | Carcinoma, Ductal | 2 | 2011 | 11 | 0.160 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 14 | 0.160 |
Why?
| | Lymphangiogenesis | 2 | 2018 | 24 | 0.160 |
Why?
| | Parenting | 1 | 2022 | 256 | 0.160 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 22 | 0.160 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2018 | 11 | 0.160 |
Why?
| | Cisplatin | 1 | 2020 | 263 | 0.160 |
Why?
| | Ipilimumab | 1 | 2018 | 28 | 0.160 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2019 | 60 | 0.160 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 388 | 0.160 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2019 | 106 | 0.150 |
Why?
| | Vitamin D | 1 | 2021 | 341 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2018 | 340 | 0.150 |
Why?
| | Area Under Curve | 1 | 2018 | 277 | 0.150 |
Why?
| | Global Health | 1 | 2020 | 290 | 0.150 |
Why?
| | Tretinoin | 1 | 2018 | 123 | 0.150 |
Why?
| | Tryptophan | 1 | 2018 | 136 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 193 | 0.150 |
Why?
| | Immunity, Mucosal | 1 | 2018 | 85 | 0.150 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1088 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 631 | 0.150 |
Why?
| | Drug Delivery Systems | 2 | 2010 | 301 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2020 | 3054 | 0.150 |
Why?
| | Depression | 3 | 2020 | 1145 | 0.140 |
Why?
| | Patient Care Management | 1 | 2017 | 55 | 0.140 |
Why?
| | Granulocytes | 1 | 2017 | 78 | 0.140 |
Why?
| | Mammography | 1 | 2017 | 107 | 0.140 |
Why?
| | Genetic Testing | 2 | 2016 | 383 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 577 | 0.140 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 65 | 0.140 |
Why?
| | Metaplasia | 1 | 2016 | 54 | 0.140 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 47 | 0.140 |
Why?
| | Prostatic Neoplasms | 2 | 2021 | 927 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 394 | 0.140 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 30 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 312 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 504 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2206 | 0.130 |
Why?
| | Chronic Pain | 1 | 2019 | 210 | 0.130 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1995 | 11 | 0.130 |
Why?
| | Cellular Microenvironment | 1 | 2016 | 78 | 0.130 |
Why?
| | Levodopa | 1 | 1995 | 23 | 0.130 |
Why?
| | Antiparkinson Agents | 1 | 1995 | 26 | 0.130 |
Why?
| | Epithelium | 2 | 2015 | 297 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 301 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 91 | 0.130 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2015 | 8 | 0.130 |
Why?
| | Rats | 6 | 2021 | 5035 | 0.130 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2015 | 5 | 0.130 |
Why?
| | Cytophagocytosis | 1 | 2015 | 10 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2021 | 12615 | 0.130 |
Why?
| | Phosphoproteins | 2 | 2015 | 302 | 0.130 |
Why?
| | Pyrimidines | 1 | 2018 | 376 | 0.130 |
Why?
| | Adherens Junctions | 1 | 2015 | 26 | 0.130 |
Why?
| | Paracrine Communication | 1 | 2015 | 56 | 0.130 |
Why?
| | United States | 6 | 2022 | 12319 | 0.120 |
Why?
| | Menarche | 1 | 2015 | 49 | 0.120 |
Why?
| | Survivors | 3 | 2023 | 404 | 0.120 |
Why?
| | Spleen | 1 | 2017 | 492 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2016 | 118 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 196 | 0.120 |
Why?
| | Extracellular Matrix | 2 | 2016 | 439 | 0.120 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1056 | 0.120 |
Why?
| | Lymph Node Excision | 2 | 2021 | 141 | 0.120 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 336 | 0.120 |
Why?
| | Male | 19 | 2022 | 56103 | 0.120 |
Why?
| | Microfilament Proteins | 1 | 2015 | 127 | 0.120 |
Why?
| | Survival Analysis | 4 | 2021 | 1218 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2022 | 4673 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 537 | 0.120 |
Why?
| | Genes, BRCA2 | 2 | 2015 | 26 | 0.120 |
Why?
| | Amenorrhea | 1 | 2014 | 27 | 0.120 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2014 | 28 | 0.120 |
Why?
| | Genes, BRCA1 | 2 | 2015 | 33 | 0.120 |
Why?
| | Odds Ratio | 4 | 2020 | 968 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4447 | 0.120 |
Why?
| | Signal Transduction | 4 | 2020 | 4527 | 0.120 |
Why?
| | Brain Edema | 1 | 2014 | 59 | 0.120 |
Why?
| | Spouses | 1 | 2015 | 84 | 0.120 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 206 | 0.120 |
Why?
| | Collagen | 2 | 2021 | 415 | 0.120 |
Why?
| | Tremor | 1 | 1994 | 45 | 0.120 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1443 | 0.120 |
Why?
| | Monocytes | 1 | 2017 | 504 | 0.120 |
Why?
| | Astrocytes | 1 | 2015 | 165 | 0.110 |
Why?
| | Nitriles | 1 | 2014 | 152 | 0.110 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 59 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 783 | 0.110 |
Why?
| | Mice, Inbred C57BL | 6 | 2019 | 4779 | 0.110 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2019 | 53 | 0.110 |
Why?
| | Infertility, Female | 1 | 2014 | 94 | 0.110 |
Why?
| | Triazoles | 1 | 2014 | 131 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 935 | 0.110 |
Why?
| | Trans-Activators | 1 | 2015 | 369 | 0.110 |
Why?
| | Lymphatic Vessels | 3 | 2019 | 54 | 0.110 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 25 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1277 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2013 | 127 | 0.100 |
Why?
| | Transcriptome | 2 | 2021 | 742 | 0.100 |
Why?
| | Live Birth | 2 | 2023 | 48 | 0.100 |
Why?
| | Germ Cells | 2 | 2022 | 62 | 0.100 |
Why?
| | Wound Healing | 1 | 2014 | 262 | 0.100 |
Why?
| | Logistic Models | 5 | 2016 | 1863 | 0.100 |
Why?
| | Drug Design | 1 | 2013 | 156 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2021 | 1664 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2021 | 9163 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2015 | 342 | 0.100 |
Why?
| | Genes, Bacterial | 1 | 2012 | 156 | 0.100 |
Why?
| | Apoptosis | 3 | 2019 | 2377 | 0.100 |
Why?
| | Fibrillar Collagens | 1 | 2011 | 12 | 0.100 |
Why?
| | Parkinson Disease | 1 | 1995 | 325 | 0.100 |
Why?
| | Patient Participation | 1 | 2015 | 362 | 0.100 |
Why?
| | Progesterone | 1 | 2013 | 232 | 0.100 |
Why?
| | Membrane Proteins | 2 | 2015 | 1033 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 319 | 0.100 |
Why?
| | Streptococcus agalactiae | 1 | 2012 | 82 | 0.090 |
Why?
| | Antigen Presentation | 2 | 2018 | 189 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 703 | 0.090 |
Why?
| | Adenocarcinoma | 2 | 2015 | 797 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 39 | 0.090 |
Why?
| | Sexual Behavior | 1 | 2014 | 440 | 0.090 |
Why?
| | Clinical Trials as Topic | 3 | 2017 | 944 | 0.090 |
Why?
| | Cell Fusion | 2 | 2006 | 50 | 0.090 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 66 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2021 | 182 | 0.080 |
Why?
| | Cell Movement | 3 | 2019 | 867 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2021 | 98 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2010 | 184 | 0.080 |
Why?
| | Mucin-1 | 1 | 2009 | 18 | 0.080 |
Why?
| | Reference Standards | 2 | 2012 | 162 | 0.080 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 4 | 2016 | 2262 | 0.080 |
Why?
| | Macrophage Activation | 1 | 2010 | 165 | 0.080 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 129 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 310 | 0.080 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 20 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 174 | 0.080 |
Why?
| | Quinolines | 2 | 2021 | 129 | 0.080 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2020 | 47 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2020 | 6434 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 1871 | 0.080 |
Why?
| | Interferon-beta | 1 | 2008 | 80 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1725 | 0.080 |
Why?
| | Metalloproteases | 1 | 2008 | 37 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2009 | 128 | 0.080 |
Why?
| | Age of Onset | 2 | 2021 | 455 | 0.080 |
Why?
| | Genomics | 2 | 2023 | 653 | 0.080 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 124 | 0.080 |
Why?
| | Cell Cycle | 2 | 2021 | 546 | 0.070 |
Why?
| | HIV Infections | 1 | 2001 | 2471 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1264 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 351 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2018 | 182 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2009 | 321 | 0.070 |
Why?
| | ErbB Receptors | 3 | 2017 | 557 | 0.070 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 303 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 17 | 0.070 |
Why?
| | Child | 6 | 2022 | 18537 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 433 | 0.070 |
Why?
| | Mice, Nude | 3 | 2015 | 639 | 0.070 |
Why?
| | Mammaplasty | 2 | 2021 | 68 | 0.070 |
Why?
| | Ovariectomy | 2 | 2019 | 117 | 0.070 |
Why?
| | Cell Survival | 2 | 2020 | 1024 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1001 | 0.070 |
Why?
| | Postmenopause | 2 | 2005 | 301 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2019 | 3914 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2023 | 5084 | 0.070 |
Why?
| | Administration, Oral | 2 | 2018 | 733 | 0.070 |
Why?
| | Fear | 2 | 2021 | 296 | 0.070 |
Why?
| | Axilla | 2 | 2021 | 39 | 0.070 |
Why?
| | Models, Biological | 2 | 2012 | 1647 | 0.070 |
Why?
| | Forkhead Transcription Factors | 2 | 2018 | 170 | 0.060 |
Why?
| | Dendritic Cells | 2 | 2005 | 438 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 758 | 0.060 |
Why?
| | Solubility | 1 | 2005 | 226 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2014 | 1227 | 0.060 |
Why?
| | Neoplastic Processes | 1 | 2023 | 4 | 0.060 |
Why?
| | Cancer Vaccines | 1 | 2005 | 137 | 0.060 |
Why?
| | Multiple Myeloma | 1 | 2005 | 93 | 0.060 |
Why?
| | Weaning | 2 | 2016 | 48 | 0.060 |
Why?
| | Celecoxib | 2 | 2014 | 38 | 0.050 |
Why?
| | Peptides | 1 | 2008 | 864 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 13 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 33 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2022 | 15 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2023 | 69 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 46 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 647 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 53 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 62 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4122 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 136 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 310 | 0.050 |
Why?
| | Heterozygote | 1 | 2022 | 254 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2012 | 2807 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 485 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2021 | 40 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 84 | 0.050 |
Why?
| | Genes, p53 | 1 | 2021 | 62 | 0.050 |
Why?
| | Hypertrophy | 1 | 2021 | 112 | 0.050 |
Why?
| | Placebos | 1 | 2021 | 198 | 0.050 |
Why?
| | Protective Agents | 1 | 2021 | 38 | 0.050 |
Why?
| | In Situ Hybridization | 1 | 2001 | 298 | 0.050 |
Why?
| | DNA Replication | 1 | 2022 | 204 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2022 | 437 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 967 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 105 | 0.050 |
Why?
| | DNA Repair | 1 | 2022 | 192 | 0.050 |
Why?
| | Immunity | 1 | 2021 | 125 | 0.050 |
Why?
| | Hormones | 1 | 2021 | 132 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 249 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2013 | 1060 | 0.050 |
Why?
| | Pregnancy Rate | 1 | 2020 | 55 | 0.050 |
Why?
| | Hospitals, University | 1 | 2021 | 172 | 0.050 |
Why?
| | Arm | 1 | 2021 | 105 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2004 | 325 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 413 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 278 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 9 | 0.040 |
Why?
| | SEER Program | 1 | 2021 | 195 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2021 | 186 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2020 | 309 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 341 | 0.040 |
Why?
| | Immunotherapy | 2 | 2014 | 481 | 0.040 |
Why?
| | DNA, Viral | 1 | 2001 | 351 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4443 | 0.040 |
Why?
| | Sulfonamides | 2 | 2014 | 447 | 0.040 |
Why?
| | Fibronectins | 1 | 2020 | 108 | 0.040 |
Why?
| | Unemployment | 1 | 2019 | 39 | 0.040 |
Why?
| | Vaginal Diseases | 1 | 2019 | 17 | 0.040 |
Why?
| | Base Sequence | 2 | 2016 | 2121 | 0.040 |
Why?
| | Leuprolide | 1 | 2019 | 20 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 454 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 64 | 0.040 |
Why?
| | Hot Flashes | 1 | 2019 | 72 | 0.040 |
Why?
| | Interleukin-10 | 2 | 2014 | 304 | 0.040 |
Why?
| | Crosses, Genetic | 1 | 2018 | 141 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2019 | 261 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2019 | 115 | 0.040 |
Why?
| | Phenotype | 2 | 2020 | 2859 | 0.040 |
Why?
| | Integrins | 1 | 2018 | 79 | 0.040 |
Why?
| | Body Weight | 1 | 2022 | 868 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 80 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 83 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 107 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 138 | 0.040 |
Why?
| | Weight Loss | 1 | 2022 | 633 | 0.040 |
Why?
| | Contraceptives, Oral | 1 | 2017 | 25 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 545 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2021 | 585 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2021 | 460 | 0.040 |
Why?
| | Behavior | 1 | 2018 | 91 | 0.040 |
Why?
| | Educational Status | 1 | 2019 | 413 | 0.040 |
Why?
| | Tumor Escape | 1 | 2017 | 35 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 2992 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 1974 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 817 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2016 | 40 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 962 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 44 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1217 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 304 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 395 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 3474 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2018 | 331 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 273 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 246 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 666 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 118 | 0.030 |
Why?
| | Cognition | 1 | 2022 | 980 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2015 | 79 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 348 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 180 | 0.030 |
Why?
| | Hybrid Cells | 2 | 2005 | 49 | 0.030 |
Why?
| | Directive Counseling | 1 | 2015 | 41 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2015 | 72 | 0.030 |
Why?
| | Child, Preschool | 2 | 2021 | 9164 | 0.030 |
Why?
| | Terminal Care | 1 | 2018 | 212 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 273 | 0.030 |
Why?
| | Tumor Burden | 1 | 2015 | 261 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 75 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 242 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1830 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2013 | 42 | 0.030 |
Why?
| | Dinoprostone | 1 | 2014 | 188 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 148 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 422 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 52 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 137 | 0.030 |
Why?
| | Dermoscopy | 1 | 2013 | 9 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 211 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 220 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 283 | 0.030 |
Why?
| | Oncogenes | 1 | 2013 | 104 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2018 | 695 | 0.030 |
Why?
| | Family Health | 1 | 1994 | 199 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 85 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 102 | 0.030 |
Why?
| | Adiposity | 1 | 2017 | 468 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 192 | 0.030 |
Why?
| | Immune System | 1 | 2014 | 173 | 0.030 |
Why?
| | Observer Variation | 1 | 2013 | 298 | 0.030 |
Why?
| | Menopause | 1 | 2015 | 262 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2013 | 177 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1476 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2608 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 950 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2404 | 0.030 |
Why?
| | Calibration | 1 | 2012 | 127 | 0.030 |
Why?
| | Cell Division | 1 | 2013 | 760 | 0.030 |
Why?
| | Palliative Care | 1 | 2018 | 642 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2004 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1709 | 0.020 |
Why?
| | Interferon-gamma | 2 | 2005 | 733 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2590 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 750 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2012 | 173 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 700 | 0.020 |
Why?
| | Genome, Human | 1 | 2013 | 372 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 321 | 0.020 |
Why?
| | Universities | 1 | 2013 | 341 | 0.020 |
Why?
| | Photochemotherapy | 1 | 2010 | 29 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2657 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1065 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1649 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 284 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2014 | 467 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 299 | 0.020 |
Why?
| | Keratin-19 | 1 | 2009 | 2 | 0.020 |
Why?
| | Immunomagnetic Separation | 1 | 2009 | 3 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 87 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 19 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1359 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2009 | 82 | 0.020 |
Why?
| | Vinblastine | 1 | 2009 | 61 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 67 | 0.020 |
Why?
| | Sex Factors | 1 | 1994 | 1741 | 0.020 |
Why?
| | Flavonoids | 1 | 2009 | 68 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1153 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 553 | 0.020 |
Why?
| | ADAM12 Protein | 1 | 2008 | 4 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2270 | 0.020 |
Why?
| | ADAM Proteins | 1 | 2008 | 60 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 39 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 59 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 97 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 118 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 514 | 0.020 |
Why?
| | Radiotherapy | 1 | 2008 | 177 | 0.020 |
Why?
| | Piperidines | 1 | 2009 | 163 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1442 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 501 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 156 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2008 | 466 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 804 | 0.020 |
Why?
| | Pleural Effusion | 1 | 2006 | 46 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 754 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 43 | 0.020 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 24 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 47 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 43 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2005 | 97 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 285 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2005 | 110 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2012 | 975 | 0.020 |
Why?
| | Hemocyanins | 1 | 2004 | 57 | 0.020 |
Why?
| | Patient Care Planning | 1 | 2005 | 142 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 204 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 703 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2006 | 554 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 293 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2372 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 850 | 0.010 |
Why?
| | Paclitaxel | 1 | 2003 | 192 | 0.010 |
Why?
| | Pilot Projects | 1 | 2003 | 1379 | 0.010 |
Why?
| | Vaccination | 1 | 2004 | 1209 | 0.010 |
Why?
|
|
Borges's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|